Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

This study is testing whether adding orelabrutinib (a targeted therapy that blocks a cancer-driving protein called BTK) to the standard R-CHOP chemotherapy regimen works better for a specific subtype of aggressive lymphoma called CD5-positive diffuse large B-cell lymphoma (DLBCL). **You may be eligible if...** - You are 18 or older - You have been diagnosed with CD5-positive DLBCL confirmed by biopsy - You have at least one measurable tumor - You are in good physical condition (ECOG 0–2) - Your bone marrow, liver, and kidney function are sufficient - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have DLBCL that has transformed from another lymphoma type - The cancer has spread to your central nervous system (brain/spinal cord) - You have previously received a BTK inhibitor - You have active serious infections Talk to your doctor to see if this trial is right for you.